ADRESTIA THERAPEUTICS
Adrestia Therapeutics are leaders in synthetic rescue, an approach that decodes the complexity of genetic networks to reveal new ways to treat diseases.
ADRESTIA THERAPEUTICS
Industry:
Biotechnology
Founded:
2017-01-01
Address:
Babraham, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.adrestia.com
Total Employee:
11+
Status:
Closed
Contact:
+44 01223 804142
Email Addresses:
[email protected]
Total Funding:
172 M GBP
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS WP Engine Apple ICloud Mail NSONE
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Applied Molecular Transport
Applied Molecular Transport developing novel, oral biological therapeutics to treat severe autoimmune, metabolic and inflammatory diseases.
Memo Therapeutics
Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.
Current Advisors List
Current Employees Featured
Founder
Investors List
Ahren Innovation Capital
Ahren Innovation Capital investment in Series A - Adrestia Therapeutics
GlaxoSmithKline
GlaxoSmithKline investment in Series A - Adrestia Therapeutics
Ahren Innovation Capital
Ahren Innovation Capital investment in Seed Round - Adrestia Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2022-03-03 | Adrestia Appoints Robert Johnson as Chief Executive Officer |
Official Site Inspections
http://www.adrestia.com
- Host name: 199.59.243.228
- IP address: 199.59.243.228
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Adrestia Therapeutics"
Adrestia R&D – Equilibrium in Research And Development
Adrestia has been actively contributing to the European research and innovation landscape for over four years. With a steadfast presence in EU-funded initiatives, we have successfully …See details»
Adrestia Acquired by Insmed Incorporated, Bringing its …
Aug 3, 2023 Adrestia is part of Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a ...See details»
About – Adrestia R&D
Adrestia was established in 2020, with the main objective of reaching an equilibrium in Research and Development and uniting the best of the two worlds. Adrestia’s R&D personnel comprises …See details»
Adrestia Therapeutics - Crunchbase Company Profile & Funding
Adrestia Therapeutics closed its last funding round on Dec 18, 2020 from a Series A round. Who are Adrestia Therapeutics 's competitors? Alternatives and possible competitors to Adrestia …See details»
Adrestia Acquired by Insmed Incorporated, Bringing its Novel …
Aug 3, 2023 Adrestia was co-founded by Professor Sir Steve Jackson and the deep technology investment fund Ahren Innovation Capital. Adrestia is part of Insmed Incorporated, a global …See details»
Consortium – OASEES
Adrestia was established in 2020, with the main objective to reach an equilibrium in Research and Development, and unite the best of the two worlds. ... CEA is an organization in France that …See details»
Insmed acquires Adrestia Therapeutics - 2023-06-30 - Crunchbase
Jun 30, 2023 Adrestia Therapeutics Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells. Acquiring …See details»
Adrestia Therapeutics Ltd. - life-sciences-europe.com
Aug 25, 2017 Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and …See details»
☑️Adrestia — Consulting Organization from Greece, experience …
Adrestia — Consulting Organization from Greece, has experience with Horizon 2020 (2014 - 2020), Horizon Europe (2021 - 2027), it`s involved in Information & Communication …See details»
GSK and Ahren Announce Co-Led Series A Investment in Adrestia, …
Dec 18, 2020 Adrestia Therapeutics was founded in the UK in 2018, by Professor Steve Jackson together with Ahren, a $250M deep science and deep technology investment fund. …See details»
Adrestia appoints Will Lewis as Chair, establishes US …
Sep 29, 2022 Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and cardiomyopathic diseases.See details»
GSK partners with precision medicine-focused Adrestia on drug ...
Cambridge, England-based Adrestia will be eligible to receive post-option milestone payments of up to $230 million from each project, as well as royalties. GSK will make an undisclosed up …See details»
GSK invests in new field of genetic rebalancing - Financial Times
Dec 18, 2020 Adrestia was founded in 2018 by Cambridge biology professor Steve Jackson and is built around a new scientific concept called “synthetic viability”. This aims to restore …See details»
Adrestia Therapeutics Ltd - VentureRadar
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells. ... Dansk Biotek Unknown n/a DANISH …See details»
GSK and Adrestia and Enter into Precision Medicine Discovery ...
Dec 18, 2020 Adrestia’s platform can be applied to diverse therapeutic areas, which are caused by faulty molecular pathways that lead to cellular dysfunction or death. Through this approach …See details»
GSK and Ahren Announce Co-Led Series A Investment in Adrestia, …
Dec 18, 2020 Adrestia Therapeutics was founded in the UK in 2018, by Professor Steve Jackson together with Ahren, a $250M deep science and deep technology investment fund. …See details»
Adrestia Therapeutics Information - RocketReach
We are leaders in synthetic rescue, an approach that decodes the complexity of genetic networks to reveal new ways to treat diseases. Decades of research from the laboratory of synthetic …See details»
Adrestia Therapeutics - Updates, News, Events, Signals & Triggers
Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells. Search Crunchbase. Start Free Trial . Chrome …See details»
Adrestia Therapeutics Partners with Leading Patient Advocacy …
Feb 8, 2023 Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia’s Series A financing along …See details»
Adrestia Therapeutics - Contacts, Employees, Board Members
Organization. Adrestia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 6. Number of …See details»